122 related articles for article (PubMed ID: 24203631)
1. Anti-TNF antibodies do not induce the apoptosis of lamina propria mononuclear cells in uninflamed intestinal tissue in patients with Crohn's disease.
Eder P; Lykowska-Szuber L; Krela-Kazmierczak I; Stawczyk-Eder K; Sterzynska K; Iwanik K; Majewski P; Zabel M; Linke K
Folia Histochem Cytobiol; 2013; 51(3):239-43. PubMed ID: 24203631
[TBL] [Abstract][Full Text] [Related]
2. The influence of infliximab and adalimumab on the expression of apoptosis-related proteins in lamina propria mononuclear cells and enterocytes in Crohn's disease - an immunohistochemical study.
Eder P; Lykowska-Szuber L; Krela-Kazmierczak I; Stawczyk-Eder K; Zabel M; Linke K
J Crohns Colitis; 2013 Oct; 7(9):706-16. PubMed ID: 23021876
[TBL] [Abstract][Full Text] [Related]
3. Antibodies against tumor necrosis factor (TNF) induce T-cell apoptosis in patients with inflammatory bowel diseases via TNF receptor 2 and intestinal CD14⁺ macrophages.
Atreya R; Zimmer M; Bartsch B; Waldner MJ; Atreya I; Neumann H; Hildner K; Hoffman A; Kiesslich R; Rink AD; Rau TT; Rose-John S; Kessler H; Schmidt J; Neurath MF
Gastroenterology; 2011 Dec; 141(6):2026-38. PubMed ID: 21875498
[TBL] [Abstract][Full Text] [Related]
4. Prediction of antitumour necrosis factor clinical efficacy by real-time visualisation of apoptosis in patients with Crohn's disease.
Van den Brande JM; Koehler TC; Zelinkova Z; Bennink RJ; te Velde AA; ten Cate FJ; van Deventer SJ; Peppelenbosch MP; Hommes DW
Gut; 2007 Apr; 56(4):509-17. PubMed ID: 17082252
[TBL] [Abstract][Full Text] [Related]
5. Infliximab but not etanercept induces apoptosis in lamina propria T-lymphocytes from patients with Crohn's disease.
Van den Brande JM; Braat H; van den Brink GR; Versteeg HH; Bauer CA; Hoedemaeker I; van Montfrans C; Hommes DW; Peppelenbosch MP; van Deventer SJ
Gastroenterology; 2003 Jun; 124(7):1774-85. PubMed ID: 12806611
[TBL] [Abstract][Full Text] [Related]
6. Infliximab treatment induces apoptosis of lamina propria T lymphocytes in Crohn's disease.
ten Hove T; van Montfrans C; Peppelenbosch MP; van Deventer SJ
Gut; 2002 Feb; 50(2):206-11. PubMed ID: 11788561
[TBL] [Abstract][Full Text] [Related]
7. Resistance of Crohn's disease T cells to multiple apoptotic signals is associated with a Bcl-2/Bax mucosal imbalance.
Ina K; Itoh J; Fukushima K; Kusugami K; Yamaguchi T; Kyokane K; Imada A; Binion DG; Musso A; West GA; Dobrea GM; McCormick TS; Lapetina EG; Levine AD; Ottaway CA; Fiocchi C
J Immunol; 1999 Jul; 163(2):1081-90. PubMed ID: 10395708
[TBL] [Abstract][Full Text] [Related]
8. Defective mucosal T cell death is sustainably reverted by infliximab in a caspase dependent pathway in Crohn's disease.
Di Sabatino A; Ciccocioppo R; Cinque B; Millimaggi D; Morera R; Ricevuti L; Cifone MG; Corazza GR
Gut; 2004 Jan; 53(1):70-7. PubMed ID: 14684579
[TBL] [Abstract][Full Text] [Related]
9. Mucosal expression of basic fibroblastic growth factor, syndecan 1 and tumour necrosis factor-α in Crohn's disease in deep remission under treatment with anti-TNFα antibodies.
Tursi A; Elisei W; Principi M; Inchingolo CD; Nenna R; Picchio M; Giorgio F; Ierardi E; Brandimarte G
J Gastrointestin Liver Dis; 2014 Sep; 23(3):261-5. PubMed ID: 25267953
[TBL] [Abstract][Full Text] [Related]
10. Infliximab induces apoptosis in monocytes from patients with chronic active Crohn's disease by using a caspase-dependent pathway.
Lügering A; Schmidt M; Lügering N; Pauels HG; Domschke W; Kucharzik T
Gastroenterology; 2001 Nov; 121(5):1145-57. PubMed ID: 11677207
[TBL] [Abstract][Full Text] [Related]
11. Triptolide induces suppressor of cytokine signaling-3 expression and promotes lamina propria mononuclear cells apoptosis in Crohn's colitis.
Li Y; Tian Y; Zhu W; Gong J; Zhang W; Yu C; Gu L; Li N; Li J
Int Immunopharmacol; 2013 Jun; 16(2):268-74. PubMed ID: 23643741
[TBL] [Abstract][Full Text] [Related]
12. The influence of anti-TNF therapy on CD31 and VEGF expression in colonic mucosa of Crohn's disease patients in relation to mucosal healing.
Eder P; Lykowska-Szuber L; Iwanik K; Krela-Kazmierczak I; Stawczyk-Eder K; Majewski P; Linke K; Kay EW; Wozniak A
Folia Histochem Cytobiol; 2016; 54(2):75-80. PubMed ID: 27270504
[TBL] [Abstract][Full Text] [Related]
13. Effect of tumor necrosis factor-α blockade on mucosal addressin cell-adhesion molecule-1 in Crohn's disease.
Biancheri P; Di Sabatino A; Rovedatti L; Giuffrida P; Calarota SA; Vetrano S; Vidali F; Pasini A; Danese S; Corazza GR; MacDonald TT
Inflamm Bowel Dis; 2013 Feb; 19(2):259-64. PubMed ID: 23328772
[TBL] [Abstract][Full Text] [Related]
14. Reduction of CD68+ macrophages and decreased IL-17 expression in intestinal mucosa of patients with inflammatory bowel disease strongly correlate with endoscopic response and mucosal healing following infliximab therapy.
Caprioli F; Bosè F; Rossi RL; Petti L; Viganò C; Ciafardini C; Raeli L; Basilisco G; Ferrero S; Pagani M; Conte D; Altomare G; Monteleone G; Abrignani S; Reali E
Inflamm Bowel Dis; 2013; 19(4):729-39. PubMed ID: 23448791
[TBL] [Abstract][Full Text] [Related]
15. Reduced numbers of mucosal DR(int) macrophages and increased numbers of CD103(+) dendritic cells during anti-TNF-α treatment in patients with Crohn's disease.
Dige A; Magnusson MK; Öhman L; Hvas CL; Kelsen J; Wick MJ; Agnholt J
Scand J Gastroenterol; 2016; 51(6):692-9. PubMed ID: 26784676
[TBL] [Abstract][Full Text] [Related]
16. Mucosal healing at 3 months predicts long-term endoscopic remission in anti-TNF-treated luminal Crohn's disease.
af Björkesten CG; Nieminen U; Sipponen T; Turunen U; Arkkila P; Färkkilä M
Scand J Gastroenterol; 2013 May; 48(5):543-51. PubMed ID: 23477356
[TBL] [Abstract][Full Text] [Related]
17. A role for TNF-alpha and mucosal T helper-1 cytokines in the pathogenesis of Crohn's disease.
Plevy SE; Landers CJ; Prehn J; Carramanzana NM; Deem RL; Shealy D; Targan SR
J Immunol; 1997 Dec; 159(12):6276-82. PubMed ID: 9550432
[TBL] [Abstract][Full Text] [Related]
18. Functional modulation of Crohn's disease myofibroblasts by anti-tumor necrosis factor antibodies.
Di Sabatino A; Pender SL; Jackson CL; Prothero JD; Gordon JN; Picariello L; Rovedatti L; Docena G; Monteleone G; Rampton DS; Tonelli F; Corazza GR; MacDonald TT
Gastroenterology; 2007 Jul; 133(1):137-49. PubMed ID: 17631138
[TBL] [Abstract][Full Text] [Related]
19. Anti-TNF-α antibodies improve intestinal barrier function in Crohn's disease.
Noth R; Stüber E; Häsler R; Nikolaus S; Kühbacher T; Hampe J; Bewig B; Schreiber S; Arlt A
J Crohns Colitis; 2012 May; 6(4):464-9. PubMed ID: 22398062
[TBL] [Abstract][Full Text] [Related]
20. Crohn's disease outpatients treated with adalimumab have an earlier secondary loss of response and requirement for dose escalation compared to infliximab: a real life cohort study.
Ma C; Huang V; Fedorak DK; Kroeker KI; Dieleman LA; Halloran BP; Fedorak RN
J Crohns Colitis; 2014 Nov; 8(11):1454-63. PubMed ID: 24947334
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
